← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Onconova Therapeutics, Inc.
Newtown, PA
$2,154,943
Total funding
9
Grants
Funding over time
peak $825.8K · FY2005–11$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
Funding mix
By agency
NIH$2,154,943 · 9
By mechanism
R43$1,205,486 · 7
R44$745,713 · 1
R41$203,744 · 1
Investigators at Onconova Therapeutics, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Use of Novel Cox-2 Inhibitors in Neurological Disorders$471,502
R44 · FY2005 · NS
Development of a Selective PLK2 Inhibitor for Cancer Therapy$275,861
R43 · FY2011 · CA
Use of Novel Cox-2 Inhibitors in Neurological Disorders$274,211
R44 · FY2006 · NS
Development of a Small Molecule-Targeted Therapy for Mantle Cell Lymphoma$220,180
R43 · FY2008 · CA
Novel Cyclooxygenase-2 Inhibitors: Epileptogenesis$218,796
R43 · FY2005 · HL
Identification of Small Pharmacologic Inhibitors of HIV-1 Replication$203,744
R41 · FY2007 · MH
Evaluation of novel cytotoxic compounds for immunoconjugates$155,103
R43 · FY2007 · CA
Novel Therapeutic Strategy for Gliomas$135,546
R43 · FY2005 · CA
Pre-clinical Developmemt of a Novel COX-2 Inhibitor$100,000
R43 · FY2003 · CA
Use of Novel Cox-2 Inhibitors in Neurological Disorders$100,000
R43 · FY2003 · NS